Morphine for Dyspnea in Pulmonary Fibrosis

NCT04497831 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-08-04

No results posted yet for this study

Summary

"Determination of the effectiveness of nebulized morphine in the treatment of dyspnea in patients with advanced idiopathic pulmonary fibrosis"

Conditions

  • Idiopathic Pulmonary Fibrosis (IPF)

Interventions

DRUG

Morphine hydrochloride

5 mg milligram(s) per day per two days of dosage

DRUG

Placebo

Inhalation use

Sponsors & Collaborators

  • Medical University of Gdansk

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-21
Primary Completion
2022-09-21
Completion
2022-09-21

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04497831 on ClinicalTrials.gov